TO:           ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS             

FROM:     NRG Oncology Operations

DATE:      July 26, 2019


NRG-GY014 suspended to endometrial patients, ovarian suspension imminent

 

Protocol Title: “A Phase II Study of Tazemetostat (EPZ-6438) (IND #138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma”

Study Chair:  Ramez Eskander, M.D., (858) 822-6199; email: reskander@ucsd.edu

 

This study has reached the maximum allowable accrual for the endometrial patients (stage 1 accrual is complete). Accrual to the endometrial patients has been suspended today: July 26, 2019.The study may reopen to this population in 6 to 9 months after an efficacy and toxicity evaluation. The study remains open to ovarian patients but population is nearing the maximum allowable accrual and may suspend at any time. Please alert any ovarian patients you may be consenting that the trial is very close to meeting accrual goal and they may not be able to be entered.

Twitter
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse